# Eczema vs. Psoriasis: Key Differences, Side by Side

> Eczema causes intense itch in skin folds with poorly defined edges.

*Eczema (atopic dermatitis) and psoriasis are both chronic inflammatory skin diseases driven by immune dysregulation, but their pathophysiology, appearance, distribution, itch intensity, triggers, and treatments differ significantly. Eczema is driven by Th2 cytokines (IL-4, IL-13, IL-31) and a defective epidermal barrier; it appears in flexural creases with poorly defined edges and severe itch. Psoriasis is driven by the Th17/IL-23 axis causing rapid keratinocyte proliferation, producing well-defined, silvery-scaled plaques on extensor surfaces (elbows, knees, scalp) with milder itch.*

- Canonical: https://beautycomparison.com/eczema-vs-psoriasis
- Reviewed: 2026-06-20
- Publisher: Beauty Comparison (Beauty Comparison Editorial) — independent, brand-neutral

## Key takeaways
- The itch difference is the most reliable clinical clue: eczema itch is typically described as intense, relentless, and burning — often severe enough to disrupt sleep; psoriasis itch is usually mild to moderate, though never absent.
- Eczema lives in skin folds (inner elbows, behind knees, eyelids, neck); psoriasis prefers extensor surfaces (outside of elbows, knees, scalp, lower back, nails) — the distribution is almost mirrored.
- Eczema plaques have poorly defined, blurring edges that blend into surrounding skin; psoriasis plaques have sharply demarcated, well-defined borders — a key visual distinction at a glance.
- Eczema is primarily a Th2-driven disease; psoriasis is driven by the Th17/IL-23 axis. This means biologics for one condition — dupilumab for eczema, IL-17 or IL-23 inhibitors for psoriasis — do not cross over, and occasionally worsen the other condition.
- Secondary infection is far more common in eczema than psoriasis: S. aureus colonizes >90% of eczema patients; psoriasis does not have this susceptibility.
- Both conditions can co-occur — a systematic review and meta-analysis found that people with atopic dermatitis have a 1.5–2× higher odds of also having psoriasis than the general population.

## Why Getting the Diagnosis Right Matters

[Eczema](/eczema-guide) and [psoriasis](/psoriasis-skin-guide) are among the most commonly confused skin conditions — both produce red, scaly, itchy patches, affect similar age groups, and can appear on overlapping body areas. But they are fundamentally different diseases with distinct immune pathways, triggers, and treatments.

Misidentifying one for the other leads to inappropriate treatment: topical steroids help both in the short term, masking the confusion — but longer-term management diverges substantially. Dupilumab (the biologic for eczema) can worsen psoriasis; conversely, the IL-17 inhibitors used for psoriasis have no role in eczema. Getting the diagnosis right from a dermatologist is worth the effort.

This guide sets them side by side across every clinically relevant dimension.

---

## At a Glance: The Key Differences

| Feature | Eczema (Atopic Dermatitis) | Psoriasis (Plaque) |
|---|---|---|
| **Primary immune driver** | Th2 (IL-4, IL-13, IL-31) | Th17/Th1 (IL-17, IL-23, TNF-α) |
| **Skin barrier** | Structurally defective (filaggrin mutations) | Normal structural barrier; immune-driven turnover |
| **Typical age of onset** | Infancy/childhood (45% by 6 months) | Any age, but peaks in teens–30s and 50s–60s |
| **Primary distribution** | Flexural creases: inner elbows, behind knees, face, neck | Extensor surfaces: elbows, knees, scalp, lower back, nails |
| **Lesion edges** | Poorly defined — blend into surrounding skin | Well-defined, sharp borders |
| **Scale quality** | Fine, flaking — may be absent in acute weeping | Thick, silvery-white, built-up plaques |
| **Itch intensity** | Severe — often described as intolerable; major driver of scratching | Mild to moderate — present but less dominant |
| **Skin thickening** | Lichenification (from chronic scratching) | Primary feature — driven by keratinocyte hyperproliferation |
| **Weeping/oozing** | Common in acute flares | Uncommon |
| **S. aureus colonization** | >90% of patients | Not a characteristic feature |
| **Family history** | Atopy (asthma, hay fever, food allergy) | Psoriasis specifically; psoriatic arthritis |
| **Triggers** | External: allergens, irritants, infections | Mixed internal/external: skin injury (Koebner), infections, certain drugs |
| **Nail involvement** | Uncommon | Common — pitting, onycholysis, oil drop sign |
| **Joint involvement** | Not a feature of eczema | Psoriatic arthritis in ~30% of patients |
| **Contagious?** | No | No |

---

## Appearance: How to Tell Them Apart

### Eczema Looks Like…

- **Poorly defined, fuzzy-edged** red or inflamed patches
- Skin that **weeps serous fluid** in acute flares or **crusts with golden scabs** when superinfected with S. aureus
- **Lichenification** — the skin thickening, darkening, and accentuation of skin markings from years of scratching
- **Dry, dull, rough** skin in the surrounding area — not just the affected patches
- In darker skin tones, eczema may appear **gray, purple, or brown** rather than red — commonly missed or misdiagnosed

### Psoriasis Looks Like…

- **Well-defined plaques** with a sharp, clear boundary between affected and unaffected skin
- **Thick, overlapping silvery-white scale** on a pink-to-red base — when you scratch the scale off, you may see pinpoint bleeding (Auspitz sign)
- Lesions are **raised and palpable** — you can feel the plaque thickening before the scale is fully visible
- In darker skin tones, psoriatic plaques may appear **violet or darker with gray-toned scale** rather than the classic pink-and-silver

### The Itch Test

If you are trying to distinguish between the two before seeing a dermatologist:

**Eczema:** The itch is typically the dominant and most distressing symptom — many patients describe it as unbearable, worse at night, and associated with an almost irresistible urge to scratch. Sleep disruption from itching is the norm in moderate-to-severe eczema.

**Psoriasis:** Itch is real and can be significant, but it is usually less severe than eczema itch and is not the defining feature of psoriasis for most patients. The visual appearance (plaques) and joint symptoms (if present) are often more prominent concerns.

---

## Distribution: Where Each Disease Lives

### Eczema Distribution

Eczema's location is age-dependent and strongly associated with **flexural (bent, creased) skin surfaces**:

- **Infants:** Cheeks, forehead, scalp, outer limbs
- **Children:** Inner elbows, behind knees, wrists, ankles
- **Adults:** Inner elbows, behind knees, hands (hand eczema), face, eyelids, neck

The skin folds — where flexion creates friction, moisture, and warmth — are the hallmark territory.

### Psoriasis Distribution

Psoriasis characteristically affects **extensor (stretched, outer) surfaces** — almost the mirror image of eczema:

- **Elbows** (outer surface) — one of the most common sites
- **Knees** (outer/front surface)
- **Scalp** — psoriasis is a leading cause of scalp scaling; it does not cause permanent hair loss
- **Lower back and sacrum**
- **Nails** — pitting, oil drop discoloration, thickening, crumbling
- **Palms and soles** (palmoplantar psoriasis)
- **Genitals** (genital psoriasis — particularly inverse psoriasis)

---

## Pathophysiology: The Different Immune Battles

### Why This Matters

The immune pathways driving each disease explain why treatments designed for one do not work for the other — and occasionally worsen the other.

### Eczema: A Th2 Disease

In atopic dermatitis, the immune response is dominated by Th2 lymphocytes. Filaggrin gene mutations impair the [skin barrier](/skin-barrier-repair-guide), allowing allergens and microbes to penetrate and stimulate an exaggerated Th2 response. The key cytokines are:

- **IL-4 and IL-13:** Drive Th2 polarization, suppress barrier protein synthesis, increase IgE production
- **IL-31:** The primary driver of pruritus — acts directly on itch neurons
- **IL-5:** Promotes eosinophil recruitment

The biologic dupilumab targets the IL-4Rα receptor shared by IL-4 and IL-13, blocking both simultaneously — a specifically Th2-targeted mechanism.

### Psoriasis: A Th17/Th1 Disease

Psoriasis involves a fundamentally different immune axis. Dendritic cells activate T cells that differentiate toward Th17 and Th1 profiles. The key mediators are:

- **IL-23:** The master regulator of Th17 differentiation — the primary upstream target of modern psoriasis biologics (guselkumab, risankizumab, tildrakizumab)
- **IL-17A:** Drives keratinocyte hyperproliferation and the characteristic plaque formation — targeted by secukinumab and ixekizumab
- **TNF-α:** An early amplifier of inflammation in psoriatic plaques — targeted by etanercept, adalimumab, infliximab

The result of Th17/IL-17 activation is keratinocyte proliferation 10× faster than normal — cells that normally take 28 days to mature and shed complete the cycle in 3–4 days, producing the characteristic built-up scale.

### The Cross-Interference Risk

Because the Th2 and Th17 pathways are in a regulatory balance, blocking one can sometimes unmask the other:

- Dupilumab has been reported to trigger or worsen psoriasis in a subset of patients (dupilumab-associated psoriasis)
- IL-17 inhibitors have been reported to trigger or worsen atopic dermatitis in a subset of psoriasis patients

This cross-reactivity is well-documented in dermatology literature and is one reason accurate diagnosis before treatment selection is critical.

---

## Triggers: What Starts a Flare

### Eczema Triggers (Primarily External)

- Fragrances and perfumes
- Harsh cleansers and sodium lauryl sulfate
- Wool and rough synthetic fabrics
- Sweat and overheating
- Cold, dry weather
- Allergens: house dust mite, pet dander, pollen
- Stress (worsens, doesn't directly cause)
- Food allergens (primarily in infants: egg, milk, peanut)
- Skin infections (S. aureus superinfection is the most common)

### Psoriasis Triggers (Primarily Internal and Environmental)

- **Skin injury** — the Koebner (isomorphic) phenomenon: new plaques develop at sites of skin trauma (cuts, scratches, sunburn, tattoos, surgical scars)
- **Streptococcal throat infection** — can trigger guttate psoriasis, a characteristic small-drop presentation, particularly in children
- **Certain medications:** lithium, beta-blockers, antimalarials (e.g., hydroxychloroquine), NSAIDs, and abrupt withdrawal of systemic corticosteroids
- **Stress:** a well-documented trigger and amplifier
- **Alcohol consumption and smoking:** associated with disease severity and poor treatment response
- **Hormonal changes:** some women experience flare improvement in pregnancy; others worsen

---

## Treatments: Where They Overlap and Diverge

Both conditions are managed with topical corticosteroids for active flares — this is the main area of treatment overlap. Beyond that, management diverges significantly:

### Eczema-Specific Treatments

- **Topical calcineurin inhibitors** (tacrolimus, pimecrolimus) — steroid-sparing; especially for face and skin folds
- **PDE4 inhibitors** (crisaborole, roflumilast) — newer topical options for mild-to-moderate eczema
- **Topical JAK inhibitor** (ruxolitinib cream) — for mild-to-moderate eczema
- **Dupilumab** (biologic, IL-4Rα inhibitor) — the gold standard for moderate-to-severe eczema
- **Tralokinumab, lebrikizumab** (IL-13 inhibitors) — additional biologic options
- **Oral JAK inhibitors** (upadacitinib, abrocitinib) — for moderate-to-severe eczema

### Psoriasis-Specific Treatments

- **Vitamin D analogues** (calcipotriene/calcipotriol) — a first-line topical specific to psoriasis; reduces keratinocyte proliferation
- **Coal tar** — anti-proliferative topical; more relevant for scalp psoriasis
- **Narrowband UVB** — standard phototherapy (also used in eczema)
- **IL-23 inhibitors** (guselkumab, risankizumab, tildrakizumab) — highly effective biologics
- **IL-17 inhibitors** (secukinumab, ixekizumab, bimekizumab, brodalumab) — produce PASI90 in up to 70% of patients
- **TNF-α inhibitors** (adalimumab, etanercept, infliximab) — older biologics; also treat psoriatic arthritis
- **IL-12/23 inhibitor** (ustekinumab) — also approved for psoriatic arthritis

---

## When Both Are Present

It is possible to have both conditions simultaneously. A 2022 systematic review and meta-analysis published in PMC found that people with atopic dermatitis had 1.5–2× higher odds of also having psoriasis compared to the general population. This co-occurrence presents a diagnostic and therapeutic challenge — a dermatologist should guide treatment selection, as managing both simultaneously requires careful biologic choice.

---

## Summary: The Quickest Cheat Sheet

**Is it eczema?** Look for: severe itch, skin folds, poorly defined edges, weeping/crusting, starts in infancy, associated with asthma or hay fever, worse with contact with allergens or irritants.

**Is it psoriasis?** Look for: well-defined silvery plaques, extensor surfaces, milder itch, nail changes, family history of psoriasis specifically, Koebner response to skin injury, possible joint symptoms.

When in doubt — see a board-certified dermatologist. A skin biopsy can differentiate the two histologically when the clinical picture is ambiguous.

## FAQ
**What does eczema look like vs. psoriasis in 2026?**

The most reliable visual distinctions: eczema has poorly defined, fuzzy-edged patches that may weep, crust, and appear in flexural creases (inner elbows, behind knees, eyelids). Psoriasis has sharply demarcated plaques with thick, silvery-white scale on extensor surfaces (outside of elbows and knees, scalp). Eczema itch is typically intense and relentless; psoriasis itch is usually milder. In skin of color, eczema appears gray, purple, or brown; psoriasis plaques appear darker with gray scale rather than the classic silver. These are generalizations — both conditions vary in presentation, and a dermatologist's assessment remains the gold standard.

**Can you have both eczema and psoriasis at the same time?**

Yes — co-occurrence is real and more common than chance would predict. A 2022 systematic review and meta-analysis found that people with atopic dermatitis have approximately 1.5–2× higher odds of also having psoriasis compared to the general population. The overlap can create a diagnostic and therapeutic challenge because the biologics for each condition are distinct, and using the wrong one can worsen the other disease. A dermatologist may use a skin biopsy to distinguish the conditions histologically when the clinical picture is ambiguous, and careful biologic selection is required when treating both simultaneously.

**Is there a blood test that can tell eczema from psoriasis apart?**

No single blood test reliably distinguishes the two in clinical practice. Eczema is associated with elevated total IgE and eosinophilia in some patients, particularly those with significant atopy; psoriasis has elevated markers of inflammation (ESR, CRP) and specific HLA associations (HLA-Cw6) but these are not diagnostic in isolation. Diagnosis is clinical — based on appearance, distribution, history, and triggers. When the diagnosis is genuinely uncertain, a skin biopsy examined by a dermatopathologist is the most definitive test: the histological patterns are distinct.

**Why does dupilumab sometimes cause psoriasis?**

Dupilumab selectively blocks the Th2 (IL-4/IL-13) arm of the immune response. In the immune system, Th2 and Th17 pathways are in regulatory balance — suppressing Th2 can unmask or amplify a latent Th17 response. In susceptible individuals, this shift may trigger new-onset psoriasis or worsen subclinical psoriasis. This is termed dupilumab-associated psoriasis and is an estimated 1–4% incidence in published case series. It is a recognized clinical phenomenon, not a failure of the drug — in most patients dupilumab works as intended. When psoriasis develops on dupilumab, a dermatologist can manage it topically, assess whether to continue dupilumab, or consider switching to an alternative biologic.

**Does psoriasis itch as much as eczema?**

Psoriasis does itch — often more than people realize — but itch in eczema is typically more severe, more relentless, and more sleep-disrupting than in psoriasis. This reflects different neurological drivers: eczema itch is driven primarily by IL-31 acting on itch-specific neurons; psoriasis itch involves different mediators (histamine, neuropeptides, IL-31 to a lesser degree). Pruritus in psoriasis is reported by 60–90% of patients, but when patients are asked to rate symptom severity, itch is usually ranked below the visual appearance and joint pain (in psoriatic arthritis) as their primary concern — the reverse of eczema, where itch dominates.

## Sources
- What's the difference between eczema and psoriasis? — American Academy of Dermatology (AAD): https://www.aad.org/public/diseases/eczema/childhood/child-have/difference-psoriasis
- Eczema vs. Psoriasis: What's the Difference? — Cleveland Clinic Health Essentials: https://health.clevelandclinic.org/itchy-rash-how-to-tell-if-its-eczema-or-psoriasis
- Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis — PubMed Central / NIH (2022-05-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC9060081/
- The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis — PubMed Central / NIH (2017-11-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC5697699/
- Atopic Dermatitis: A Review of Diagnosis and Treatment — PubMed Central / NIH (2024-12-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC11627575/
- Differences in Clinical Characteristics Between Hand Eczema and Hand Psoriasis — PubMed (2025-04-01): https://pubmed.ncbi.nlm.nih.gov/40241607/

_Health information, not medical advice._